The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Rational Therapeutics for Infants and Children: Workshop Summary
A Workshop Agenda
ROUNDTABLE ON RESEARCH AND DEVELOPMENT OF DRUGS, BIOLOGICS, AND MEDICAL DEVICES
Rational Therapeutics for Infants and Children
24–25 May 1999
MONDAY, MAY 24, 1999
Opening Plenary
8:30 a.m.
Welcome and Opening Remarks
Kenneth I. Shine, M.D., President,
Institute of Medicine
8:45
Statement of Objectives, Charge to Participants, Introductions
Ronald W. Estabrook, Ph.D., Roundtable Chair, Virginia Lazenby O'Hara
Professor of Biochemistry, University of Texas Southwestern Medical Center
SESSION I: Similarities and Dissimilarities in Physiology, Metabolism, and Disease States and Responses to Therapy Among Children and Adults
Presentations in this session will address the uniqueness of children and how they are similar or dissimilar to adults with regard to physiology, drug metabolism, immunology, cognitive effects, and response to disease states and therapy. This session will provide the scientific underpinning for the subsequent sessions.
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole. Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 105
Rational Therapeutics for Infants and Children: Workshop Summary
A
Workshop Agenda
ROUNDTABLE ON RESEARCH AND DEVELOPMENT OF DRUGS, BIOLOGICS, AND MEDICAL DEVICES
Rational Therapeutics for Infants and Children
24–25 May 1999
MONDAY, MAY 24, 1999
Opening Plenary
8:30 a.m.
Welcome and Opening Remarks
Kenneth I. Shine, M.D., President,
Institute of Medicine
8:45
Statement of Objectives, Charge to Participants, Introductions
Ronald W. Estabrook, Ph.D., Roundtable Chair, Virginia Lazenby O'Hara
Professor of Biochemistry, University of Texas Southwestern Medical Center
SESSION I: Similarities and Dissimilarities in Physiology, Metabolism, and Disease States and Responses to Therapy Among Children and Adults
Presentations in this session will address the uniqueness of children and how they are similar or dissimilar to adults with regard to physiology, drug metabolism, immunology, cognitive effects, and response to disease states and therapy. This session will provide the scientific underpinning for the subsequent sessions.
OCR for page 106
Rational Therapeutics for Infants and Children: Workshop Summary
Moderator:
Sumner Yaffe, M.D., Roundtable Member,
Director, Center for Research for Mothers and Children, National Institute for Child Health and Human Development, National Institutes of Health
9:00
Characteristics of Infants and Children Versus Adults
Ralph Kauffman, M.D., Director of Medical Research Children's Mercy Hospital
9:30
Differential Drug Response of Children
John T. Wilson, M.D., Professor and Chief of Clinical Pharmacology, Department of Pediatrics, Louisiana State University Medical Center
10:00
Break
10:30
Molecular Basis of Drug Metabolism
Thierry Cresteil, Ph.D., Director of Research, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Villejuif, France
11:00
Gene Expression-Ontogeny of Drug Metabolism Steve Leeder, Pharm. D., Ph.D., Associate Professor of Pediatrics and Pharmacology, Children's Mercy Hospital
Special Address
11:30
Science, Challenges, and Children Jane Henney, M.D., Commissioner, U.S. Food and Drug Administration
12:15 p.m.
Lunch Break
SESSION H: Pharmacokinetics and Pharmacodynamics in Children Versus Adults
Presentations in Session II will identify new advances in biomedical science that are uniquely applicable to children and that could be applied to the development and testing of drugs and biologics for children.
Moderator:
Whaijen Soo, M.D., Ph.D., Roundtable Member, Vice President, Clinical Services Roche Pharmaceuticals, Hoffmann-La Roche, Inc.
OCR for page 107
Rational Therapeutics for Infants and Children: Workshop Summary
1:30 p.m.
Drug Metabolism in Children and Adolescents: Insights from Therapeutic Adventures
Greg Keams, Pharm. D., Professor of Pediatrics, Pharmacology and Therapeutics, and Chief, Division of Pediatric Clinical Pharmacology, Children's Mercy Hospital
2:00
Ontogeny of P-Glycoprotein as a Transporter
John Watchko, M.D., Associate Professor of Pediatrics, Obstetrics, Gynecology, and Reproductive Science, University of Pittsburgh School of Medicine, and Department of Pediatrics, Magee Women's Hospital
2:30
Glucose Transporters-Developmental Aspects
Sherin U. Devaskar, M.D., Professor of Pediatrics, Obstetrics, Gynecology, and Reproductive Science, University of Pittsburgh School of Medicine, and Chief of Pediatrics, Magee Women's Hospital
3:00
Formulations
Emmett Clemente, Ph.D., Chairman and Founder, Ascent Pediatrics, Inc.
3:30
Break
3:45
Anti-Infectives
Charles H. Ballow, Pharm. D., Director, Anti-Infective Research, Kaleida Health Millard Fillmore Hospital
4:15
Rational Therapeutics for Childhood Asthma
Stanley J. Szefler, M.D., Helen Wohlberg and Henry Lambert Chair in Pharmacokinetics, Director of Clinical Pharmacology, National Jewish Medical and Research Center, and Professor of Pediatrics, and Pharmacology, University of Colorado Health Sciences Center
4:45
Oncology
David Poplack, M.D., Elise C. Young Professor of Pediatric Oncology, and Head, Hematology Oncology Section, Department of Pediatrics Baylor College of Medicine and Texas Children's Cancer Center
5:15
Adjournment and Reception in the Great HaH for Roundtable Members, Participants, and Guests
OCR for page 108
Rational Therapeutics for Infants and Children: Workshop Summary
TUESDAY, MAY 25, 1999
8:00 a.m.
Opening Remarks
Ronald Estabrook, Ph.D., Roundtable Chair
SESSION III: Extrapolation of Safety and Efficacy Data for Children
This session will examine the special requirements in evaluating drugs and biologics in pediatric populations. Questions to be explored include when and how safety and efficacy data can be used for children.
Moderator:
Michael R. McGarvey, M.D., Roundtable Member, Chief Medical Officer, Blue Cross and Blue Shield of New Jersey, Inc.
8:15
Special Considerations for Evaluating Medical Devices in Infants and Children
David Feigal, Jr, M.D., Director [Designate], Center for Devices and Radiological Health, U.S. Food and Drug Administration
8:45
Defining Surrogate Endpoints and Biomarkers for Drug Action in Pediatric Trials
Robert Temple, M.D., Associate Director for Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
9:15
Prediction of Long-Term Effects on Postnatal Brain Development
Mark Batshaw, M.D., Chair of Pediatrics, George Washington University Medical Center, and Director, Children's Research Institute, Children's National Medical Center
9:45
Evaluating Biological Therapeutics in Pediatric Clinical Trials
Karen Weiss, M.D., Director, Division of Clinical Trial Design and Analysis, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
10:15
Break
OCR for page 109
Rational Therapeutics for Infants and Children: Workshop Summary
SESSION IV: Raising Awareness of Regulatory, Legal, and Ethical Issues
This session will examine the many interrelated legal and regulatory issues in evaluating new drugs and biologics for pediatric populations. The session will also examine the interrelated social and ethical concerns when evaluating drugs and biologics with children.
Moderator:
The Honorable Paul G. Rogers, J.D., Roundtable Member, Partner, Hogan & Hartson, Former Member, U.S. House of Representatives
10:30
FDA Perspective on New Regulations
Dianne Murphy, M.D., Associate Director for Pediatrics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
11:00
The Role of IRB and Data Safety Boards
Susan Ellenberg, Ph.D., Division of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
11:30
Ethics of Drug and Biologic Research in Infants and Children
Robert M. (''Skip") Nelson, M.D., Ph.D., Associate Professor of Pediatrics and Bioethics, Medical College of Wisconsin
12:00 noon
Legal and Regulatory Considerations for the Conduct of Pediatric Clinical Trials
Michael Labson, J.D., Covington & Burling
12:30 p.m.
International Pediatric Drug Development: An Industry Perspective
Steven Spielberg, M.D., Global Head, Pediatric Drug Development, R.W. Johnson Pharmaceutical Research Institute
1:00
Lunch Break
2:00
Panel Discussion Panelists:
Susan Ellenberg, Ph.D,
Michael Labson, J.D.
OCR for page 110
Rational Therapeutics for Infants and Children: Workshop Summary
Michael R. McGarvey, M.D.
Dianne Murphy, M.D.
Robert M. Nelson, M.D., Ph.D.,
The Honorable Paul G. Rogers, J.D.
Steven Spielberg, M.D.
Sumner Yaffe, M.D.
3:00
Conclusions
Murray Lumpkin, M.D., Deputy Director for Review Management, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
3:30
Closing Remarks
Ronald Estabrook, Ph.D., Roundtable Chair
4:45
Adjournment
Items in cart [0]
